Metaplastic carcinoma of the breast (MCB) is a poorly understood subtype of breast cancer. It is generally characterized by the coexistence of ductal carcinomatous and transdifferentiated sarcomatous components, but the underlying molecular alterations, possibly related to epithelial-mesenchymal transition (EMT), remain elusive. We performed transcriptional profiling using half-agenome oligonucleotide microarrays to elucidate genetic profiles of MCBs and their differences to those of ductal carcinoma of breasts (DCBs) using discarded specimens of four MCBs and 34 DCBs. Unsupervised clustering disclosed distinctive expression profiles between MCBs and DCBs. Supervised analysis identified gene signatures discriminating MCBs from DCBs and between MCB subclasses. Notably, many of the discriminator genes were associated with downregulation of epithelial phenotypes and with synthesis, remodeling and adhesion of extracellular matrix, with some of them have known or inferred roles related to EMT. Importantly, several of the discriminator genes were upregulated in a mutant Snail-transfected MCF7 cell known to exhibit features of EMT, thereby indicating a crucial role for EMT in the pathogenesis of MCBs. Finally, the identification of SPARC and vimentin as poor prognostic factors reinforced the role of EMT in cancer progression. These data advance our understanding of MCB and offer clues to the molecular alterations underlying EMT.
Introduction
Metaplastic carcinoma of the breast (MCB) is a subtype of breast cancer. Although relatively rare, its peculiar histomorphology, classically characterized by the coexistence of carcinomatous and sarcomatous components, has long been intriguing. Several names, including carcinosarcoma, spindle carcinoma and sarcomatoid carcinoma, have been given to this cancer for its heterogeneous histologic features (Thiery, 2002) . Carcinomas with these peculiar features are also encountered in other organs, including the female genital tract, lungs, prostate and urinary bladder (Thiery, 2002) . Although several lines of evidence highly suggested a monoclonal origin (Zhuang et al., 1997; Lien et al., 2004) , with the sarcomatous component converted from a carcinomatous component through a metaplastic (transdifferentiated) process (Thiery, 2002) , it is currently not known whether this morphological subtype of breast cancer is genetically distinct from the conventional ductal carcinoma of the breast (DCB). Moreover, given the bona fide carcinomatous nature of MCB, the genetic programing underlying the metaplastic process remains elusive.
In addition to its histopathological features, MCB also has clinical behavior distinct from those of DCB, including relatively large size at diagnosis, infrequent expression of hormone receptors, lower incidence of axillary nodal involvement than typical breast carcinoma of similar size, and high rate of extranodal metastasis (Carter et al., 2006; Pezzi et al., 2007) . Although presenting more commonly as node-negative disease, the outcome in MCB is generally poor with a high risk of recurrence (Barnes et al., 2005; Carter et al., 2006; Pezzi et al., 2007) . Patients with MCB usually do not benefit from conventional breast cancer chemotherapy or hormone therapy (Al Sayed et al., 2006) . Despite these distinct clinicopathologic features, the genetic basis for the recognition of MCB as a discrete subtype of breast cancer distinct from DCB is still lacking and the molecular alterations of MCB, critical for understanding the pathology of this cancer, have not yet been explored.
Epithelial-mesenchymal transition (EMT) is the process of disaggregating structured polarized epithelial units into single-motile fibroblastoid cells to enable cell movement and morphogenesis, which was originally discovered from studies of embryonic development (Zavadil and Bottinger, 2005) . The process of EMT gained wide recognition as a potential mechanism for the progression of malignancy, and was attributed to the loosening of epithelial characteristics and the acquisition of migratory and highly matrix invasive phenotypes (Thiery, 2002) . EMT is characterized by loss of proteins associated with the polarized epithelial phenotype (for example, E-cadherin and cytokeratin) and de novo synthesis of proteins associated with mesenchymal and migratory morphology of transitioning cells (for example, vimentin) (Zavadil and Bottinger, 2005) . Classically, MCB is composed of carcinomatous and sarcomatous components. Because the sarcomatous component is morphologically characterized by the less cohesive and more fibroblastoid growth patterns reminiscent of EMT, these morphological features would make metaplastic carcinoma an ideal in vivo model to study the genetic programing involved in EMT.
The purpose of this study was to investigate the molecular characteristics of MCBs and compare them with those of DCBs using microarray analysis of samples from four MCBs and 34 stage-matched DCBs. A more thorough understanding of the molecular profiles of MCBs and their distinctions from DCBs will contribute to our understanding of the pathology of this rare yet unique breast cancer and shed light on the genetic programing of EMT.
Results

Profiles of gene expression distinguish MCBs and DCBs
Representative histomorphological and immunophenotypic differences between MCBs and DCBs are shown in Figure 1a . A total of 44 breast tissue samples (4 MCBs, 34 DCBs and 6 normal breast samples) representing 44 different patients were profiled by oligonucleotide microarray technology. We initially analysed the microarray data in an unsupervised manner to determine whether there were any innate differences in the gene profiles between MCBs and DCBs. Unsupervised hierarchical clustering was performed using 4525 probes representing 4334 genes whose expression ratios varied by at least fourfold from the overall median abundance in at least one sample. We found distinctive gene expression profiles for MCBs and DCBs: the four MCBs clustered into one group and were separate from the 34 DCBs, exemplifying the inherent differences of gene expression between these two subtypes of breast cancer (Figure 1b) . Not unexpectedly, the six normal breast samples clustered together and were separate from the cancer samples.
Identification of genes differentially expressed in MCBs relative to DCBs
To identify the most discriminating profiles between MCB and DCB samples, we performed supervised hierarchical clustering, using statistical analysis of microarrays (SAM) analysis (Figure 2a) . With a false discovery rate (FDR) of 1%, a total of 213 probes representing 208 genes were found, with 87 genes overexpressed and 121 genes underexpressed in MCBs. The expression ratios and SAM scores for these 208 genes are shown in detail in Supplementary Table 1 . Of the 208 genes, 124 had known biological functions, including 61 genes that were overexpressed and 63 genes that were underexpressed in the MCBs. Most of the 126 genes were categorized into five biological processes according to Gene Ontology annotations (Ashburner et al., 2000) : cell adhesion/motility, transcription, development, signal transduction, and metabolism (Supplementary Table 2 ). Notably, several of the 87 MCB-overexpressed genes were functionally related to extracellular matrix (ECM), including genes associated with ECM synthesis (PCOLCE2, PLOD, PLOD2, CSPG4, HAS, VIM and COL27A1), remodeling (CTSZ), adhesion/motility/migration (HAPLN1, VIM, COL9A3, COL9A1, CSPG4, KINDLIN 1 and FLNA), and genes associated with skeletal development and/or chondroossification (BMP2, CSPG4 and TNFRSF11 (osteoprotegrin)). BMP2, which also has documented function related to EMT (Ma et al., 2005) , was identified among genes upregulated in MCBs. In contrast, genes encoding proteins related to maintaining epithelial phenotype, including cytoskeleton (KRT18 and KRT19), cell-cell adhesion molecules (CDH1, CEA-CAM6 and TACSTD1 (epithelial adhesion molecule)) and tight junction (EPPK1 (epiplakin 1), CLDN7, CRB3 and F11R (junctional adhesion molecule 1)), were downregulated in MCBs (Liu et al., 2000; Fujiwara et al., 2001; Lemmers et al., 2004) . ESR1 and ERBB2 were also downregulated in MCBs, consistent with universal lack of ERa and HER-2/neu expression in MCBs as compared to DCBs (Carter et al., 2006) .
Identification of genes differentially expressed in MCB subclass 2 Among the four MCBs, BT-18 and BT-19, classified as MCB subclass 1, were histologically composed predominantly of carcinomatous components and focally (o10% of the whole-tumor component) of sarcomatous components, while BT-20 and L-5, classified as MCB subclass 2, were composed predominantly of sarcomatous components, with frequent ECM formation and osteochondroid change, and focally (o10% of the whole-tumor component) of carcinomatous components (Figure 3a ). This morphological classification of the four MCBs into two subclasses was supported by the similar gene expression profiling between BT-20 and L-5 (MCB subclass 2) and between BT-18 and BT-19 (MCB subclass 1), as evidenced by correlation coefficients from scatter plotting among the four MCBs (Figure 3b) , and by the clustering of BT-20 and L-5 (MCB subclass 2) and of BT-18 and BT-19 (MCB subclass 1) in the unsupervised hierarchical clustering analysis (Figure 1b) . We hypothesized that the genetic difference between these two MCB subclasses might in someway account for the different morphological features seen between these two MCB subclasses, including the sarcomatous metaplasia and the prominent ECM formation with frequent osteochondroid change, which are features potentially related to EMT. Thus, we performed supervised hierarchical clustering using SAM analysis and disclosed 35 discriminator genes (FDR 5%). All of the 35 genes were overexpressed in MCB subclass 2 (Figure 3c ). The expression ratios and SAM scores of the 35 genes are shown in Table 1 . Twenty-seven of the 35 genes had known biological functions and most of the 27 genes were categorized into six biological processes according to Gene Ontology annotations: cell/cell matrix adhesion, development, signal transduction, metabolism, ion transport and transcription (Supplementary Table 3 ). Many of the genes were functionally related to ECM remodeling/synthesis (ADAMT5, HTRA3, MXRA8 and TIPM3), adhesion (AGC1, EDIL3 and PKD2) and structural constituent/ matricellular proteins (COL16A1, COL18A1, LUM, P4H8, SPARC, THB1 and THB2). Several other genes had functions related to development (HOXA7, MSX1, POSTN, AGC1, PRRX1, SFRP2, SFRP4 and TBX2), especially musculoskeletal/bone/cartilage development (MSX1, POSTN, AGC1, PRRX1, SFRP2 and SFRP4). Genes involved in signal transduction (PDGFA and PDGFRA), ion transport (KCNE4 and PKD2), cell division (STAG2) and muscle contraction (PPP1R12A and TPM4) were also among the genes identified by SAM analysis. . DCB showed ductal arrangement of cancer cells that were strongly stained for cytokeratin (CK) and E-cadherin (E-cad), but negative for vimentin (VIM). MCB showed a mixture of carcinomatous (CA) and sarcomatous components (SA), with the latter displaying loss of epithelial phenotypes characterized by the loss of CK and E-cad, and the gain of mesenchymal phenotypes characterized by the fibroblastoid growth of cancer cells and the strong expression of VIM (original magnification, Â 100). (b) Unsupervised hierarchical clustering of 44 samples. Data are presented in a matrix format: each row represents a gene and each column represents a sample. For each sample, the log 2 ratio of the abundance of each transcript to the abundance of each transcript in the reference sample was depicted according to a color scale (bottom left). The magnitude of deviation from the median was represented by the color saturation. The dendrogram of samples clearly revealed the distinctive gene expression profiles of MCBs and DCBs: the four MCBs clustered into one group and separated from the 34 DCBs. The six normal breast samples were clustered together and separated from cancer samples.
Confirmation of microarray data
To validate the quality of the microarray data, we examined selected genes whose expression is particularly well coordinated in breast cancer cells. Specifically, we examined the correlation coefficients for ERBB2 and GRB7 expression, with GRB7 being the neighboring gene of ERBB2 and coamplified with it, and for distinctive coexpression pairs of cytokeratins (KRTs), including KRT5/KRT14 and KRT8/KRT18. We found highly positive correlation for ERBB2/GRB7 (0.833), KRT8/ KRT18 (0.788) and KRT5/KRT14 (0.896) (Supplementary Figure 1 ), comparable to other data sets (Wilson and Dering, 2004) . Gene expression profiles were further validated by comparing ERa, PR and HER-2/neu protein expression via immunohistochemical analyses to normalized gene expression data. We found statistically significant correlation between the expression of protein and gene expression level (ERa, P ¼ 0.01 and HER-2/ neu, P ¼ 0.0001, t-test). To further confirm our microarray findings, we performed quantitative reverse transcription-PCR (QRT-PCR) analyses of several differentially expressed genes between MCBs and DCBs and between MCB subclasses. The QRT-PCR data correlated well with the expression levels, as revealed by microarray analysis; examples include those for CTSZ, FOXA1, SPARC, PDGFRA, PDGFA, SFRP4, TIMP3 and TSP1 (Figures 2b and 3d ). These genes were next validated at the protein level in paraffin-embedded archival samples by IHC (immunohistochemistry) analyses, where the availability of appropriate antibodies made this possible. As shown in Figure 3e , SPARC and PDGFRA, which were encoded by the two genes upregulated in MCB subclass 2, were strongly immunostained in the sarcomatous components, which were the predominant tumor components in MCB subclass 2. This result also confirms that at least some of those genes upregulated in MCB subclass 2 are potentially related to the sarcomatous metaplasia of this carcinoma and highlights a potential role of these genes in EMT.
Hierarchical clustering of breast cancer samples using the 35 potentially EMT-related genes revealed clustering of MCBs and DCBs Based on the distinct gene expression profiles of MCBs and DCBs and the EMT-like histologic features (sarcomatous change with ECM formation) seen in MCBs as compared to DCBs, we tested the possibility whether these 34 DCBs and 4 MCBs could be separated by hierarchical clustering using the 35 discriminator gene set derived from the MCB subclasses. Because these 35 genes were obtained by comparing the two subclasses of MCBs with relative abundance of morphological features of EMT, we hypothesized these genes might be more predictive of the genetic determinants underlying these EMT-related features. As shown in Figure 4 , the 34 DCBs were clearly separated from the four MCBs, indicating a crucial role of these potentially EMT-related genes underlying the genetic distinction of MCBs and DCBs. II; and 1537 , 1587 , 1597 , 1621 , 1623 , 1649 , 1653 and 1701 for stage III. The independent samples t-test was used to analyse the differences in the expression levels between MCBs and DCBs. DCBs, ductal carcinoma of breasts; MCBs, metaplastic carcinoma of breasts.
Validation of discriminator genes in a mutant Snail-transfected MCF7 breast cancer cell line exhibiting features of EMT Snail, a zinc-finger transcription factor, plays a fundamental role in mediating EMT (Thiery, 2002; Zhou et al., 2004) . Snail is highly unstable, but a variant of Snail (Snail-6SA) that abolishes two phosphorylation sites required, respectively, for nuclear to cytoplasmic translocation and subsequent ubiquitination, is much more stable and resides exclusively in the nucleus to induce EMT (Zhou et al., 2004) . The Snail-6SA transfectant (Snail-6SA-MCF7) exhibits features of EMT, including the fibroblastoid and migratory phenotypes together with the loss of E-cadherin and the expression of vimentin, as compared to wild-type Snailtransfectant (Snail-WT-MCF7) or parental MCF7 cell line (Figures 5a-c) (Zhou et al., 2004) . Using these cell lines as an in vitro model of EMT, we used QRT-PCR to examine whether genes differentially upregulated in the four MCBs and in MCB subclass 2, which showed prominent sarcomatous growth akin to EMT, were also upregulated in Snail-6SA-MCF7, as compared to Snail-WT-MCF7 or parental MCF7 cell lines. Based on our assumption that at least some of the 87 genes overexpressed in MCBs may be related to EMT, we selected two genes (BMP2 and VIM) implicated in EMT and two genes (IMP2 and CTSZ) with no known association with EMT. Two of the highly ranked MCB-downregulated genes (FOXA1 and TFF3) and CDH1 (E-cadherin), which was critical in preventing EMT and was underexpressed in MCBs, were also included in the validation. As shown in Figure 5d , we found that BMP2 and VIM were upregulated in Snail-6SA-MCF7 cells, consistent with the implicated roles of EMT in BMP2 and VIM. In comparison, although having no implicated role in EMT, IMP2 and CTSZ were also upregulated in Snail-6SA-MCF7 cells, suggesting a potential link between these two genes and EMT. Equally importantly, FOXA1 and TFF3, which were downregulated in the four MCBs, were also downregulated in Snail-6SA-MCF7 cells. Similarly, we selected 11 MCB subclass-2-overexpressed genes including six (PDGFRA, SFRP4, SPARC, TIMP3, PDGFA and HTRA3) high-ranked genes and five (EDIL3, THB2, ADAMT5, STAG2 and MCAM) low-ranked known genes. We found nine (SPARC, ADAMT5, MCAM, HTRA3, EDIL3, THB2, PDGFRA, TIMP3 and SFRP4) out of the 11 genes were upregulated in Snail-6SA-MCF7 cells (Figure 5d ). Collectively, these data validate the microarray-derived results in vitro and further substantiate the potential relationship of these differentially expressed genes to EMT.
Validation of a previously diagnosed MCB (diagnostic test)
To validate the diagnostic utility of these two sets of discriminator genes, respectively, for MCBs and DCBs (Supplementary Table 1) , and for MCB subclasses (Table 1) , we performed supervised hierarchical clustering on a previously diagnosed MCB (MCB-MS) that was morphologically similar to MCB subclass 2, showing predominantly sarcomatous metaplasia with osteochondroid change (Figure 6a ). In addition to the precise clustering of MCB-MS with MCBs on unsupervised clustering (Figure 6b ), we found that these two gene sets correctly clustered MCB-MS with the four MCBs studied (Figure 6c) , and clustered MCB-MS with MCB subclass 2, but not subclass 1 (Figure 6d ). This validated the diagnostic utility of the results of our microarray experiments.
Evaluation of prognostic significance using tissue microarrays Because EMT is implicated to play a key role in the invasiveness and metastasis of cancer progression and could be associated with a poor prognosis, we investigated whether these potential EMT-related genes demonstrated any correlation with prognosis in primary breast cancer tumor samples. Thus, we performed IHC analyses with antibodies against vimentin, SPARC and Table 4 ). We found statistically significant positive correlation between expression of EMT markers (vimentin and/or SPARC and/or PDGFRA) and tumor grade (P ¼ 0.000) and triple-negative status (ER, PR and HER2-negative) (P ¼ 0.027), suggesting a potential association between EMT and high-grade and triple-negative DCB. When Kaplan-Meier survival curves for overall survival were plotted, statistically significant poor prognoses were observed for vimentin-positive and SPARC-positive tumors (P ¼ 0.0001 and 0.0117, respectively, log-rank test) (Figure 7) . By multivariate analysis, both vimentin and SPARC remained independent, poor prognostic indicators (P ¼ 0.004 and 0.005, respectively, Cox regression). PDGFRA, in contrast, was not associated with poor overall survival.
Discussion
We systemically surveyed gene expression of 4 MCBs and 34 DCBs on a genome-wide scale using oligonucleotide microarray techniques. Unsupervised hierarchical clustering clearly demonstrated distinctive gene expression profiles of MCBs and DCBs, exemplifying the inherent genetic differences between these two subtypes of breast cancer. Our data provided, for the first time, the genetic basis from a global approach for the classification of these two morphologically distinctive breast cancers. Supervised hierarchical clustering disclosed 87 genes overexpressed and 121 genes underexpressed in MCBs. Most notably, several of the 87 MCB-overexpressed genes were functionally related to ECM, including genes associated with ECM synthesis, remodeling and adhesion/motility/migration, and genes associated with skeletal development and/or chondroossification. In contrast, genes encoding proteins related to maintaining epithelial phenotypes, including cytoskeleton, cell-cell adhesion molecules and tight junctions, were downregulated in MCBs. The upregulation of these ECM-related genes and the downregulation of epithelial-related genes in MCBs, especially mixed mesenchymal and epithelial MCBs, could account for the morphological features qof sarcomatous (fibroblastoid and motile) changes with ECM formation seen in MCBs, as compared to DCBs. Several other genes including ADM, ENPP2, PLAGL1 and BMP2 are also related to breast cancer. While ADM and ENPP2, potentially related to angiogenesis, are reportedly overexpressed in breast cancer (Oehler et al., 2003; Jansen et al., 2005) , PLAGL1 and BMP2 exhibit tumor suppressor activity in breast cancer based on their growth inhibitory effects and their reduced expression in cancer tissue compared to normal breast tissue (Soda et al., 1998; Bilanges et al., 1999; Reinholz et al., 2002) . Despite their potential roles in the conventional type of breast cancer, how these genes participate in the pathophysiology of MCB remains to be clarified. BMP2, one of the TGF-b superfamily members, also plays a crucial role in EMT during cardiac cushion development (Ma et al., 2005) . Since EMT is implicated in sarcomatous metaplasia of carcinoma cells in MCB (Thiery, 2002) , the identification of BMP2 as an upregulated gene in MCB and in Snail 6SA-MCF7 cells that display features of EMT further highlights a potential role for BMP2 underlying the features of EMT in MCBs and hinges on its role in EMT during cardiac cushion development. In addition, BMP2 also has a strong effect on the induction of bone formation (Ryoo et al., 2006) , a feature commonly seen in MCBs. These multiple functions, taken together, strongly suggest a crucial role for BMP2 in the pathogenesis of MCB. CCAAT/enhancer binding protein beta (C/EBPbeta), a bZIP transcription factor involved in the regulation of genes involved in immune responses and in the stimulation of expression of the collagen type I gene, induces EMT of mammary epithelia (Bundy and Sealy, 2003) . The identification of C/EBPbeta as an MCB-overexpressed gene could indicate a potential role for this transcription factor in the EMT in MCBs.
In contrast to conventional DCBs that show ER expression in more than two-thirds of cases, MCB generally lacks ER and PR expression (Barnes et al., 2005) . Very little is known about the underlying biology of ER-negative breast cancer. Using microarray analysis, Doane et al. (2006) recently identified a subset of ER(À)/PR(À) breast cancers with paradoxical expression of genes known to be either direct targets of ER, responsive to ER or typically expressed in ER( þ ) breast cancer cases. They further suggested that these ER(À) cancers might be regulated by androgens, instead of estrogen hormones. Interestingly, several of those upregulated genes overlapped with genes downregulated in MCB in our study, including AGR2, PIP, SPDEF, FOXA1, TFF3, AR, and XBP1, suggesting that MCB, despite being ER(À)/PR(À), might have hormone regulatory pathways distinct from those in the reported subset of ER(À)/PR(À) breast cancer cases. . Log 2 -fold changes of Snail-6SA-MCF7 transcript level to Snail-WT-MCF7 or MCF7 transcript level and associated standard errors were plotted. Genes upregulated in MCBs relative to ductal carcinoma of breasts (DCBs), including VIM, CTSZ, BMP2 and IMP-2, were also overexpressed in Snail-6SA-MCF7 cells (left). E-cadherin, FOXA1 and TFF3, which were underexpressed in MCB, were downregulated in Snail-6SA-MCF7 cells. Nine of the 11 genes upregulated in MCB subclass 2 relative to MCB subclass 1, including SPARC, ADAMT5, MCAM, HTRA3, EDIL3, THB2, PDGFRA, TIMP3 and SFRP4, were overexpressed in Snail-6SA-MCF7 cells (right). Consistent with western blotting and immunofluorescent staining, E-cadherin was downregulated in Snail-6SA-MCF7 cells. Equal expression levels of TATA box binding protein (TBP) were noted between these three cell lines.
In an effort to identify genes potentially related to the differences in morphological features seen between these two MCB subclasses, specifically the sarcomatous metaplasia with ECM formation and osteochondroid change, we performed supervised clustering and found 35 genes upregulated in MCB subclass 2. Expectedly, several of these genes are functionally related to synthesis, remodeling and adhesion of ECM. Notably, some of these genes are related to the matrix component of cartilage (AGC1, EDIL3, SPARC, MSX1 and ADAMT5) (Doege et al., 1991; Pfister et al., 2001; Framson and Sage, 2004; Gersch et al., 2005; Stanton et al., 2005) and bone (SPARC, MSX1 and POSTN) (Framson and Sage, 2004; Gersch et al., 2005) , which could account for the frequent osteochondroid change seen in MCB subclass 2 cancers. The identification of SPARC is of particular interest. SPARC, together with THB1 and THB2, belongs to a family of matricellular proteins functioning in mediating interactions between cells and their extracellular environments (Framson and Sage, 2004) . The immunohistochemical demonstration of the intense expression of SPARC in sarcomatous tumor cells strongly suggests a potential role for SPARC in EMT. This notion is further supported in vitro by its deadhesive and motility-increasing effects on culture cells (Framson and Sage, 2004) and in vivo by its expression in pulmonary sarcomatoid carcinoma tumor cells, but not those of conventional lung cancer (Siddiq et al., 2004) . In line with the critical role of EMT in cancer invasion and metastasis (Thiery, 2002) , we found the expression of SPARC and vimentin to be independently associated with poor overall survival in breast cancer patients, findings also confirmed by other groups (Jones et al., 2004; Korsching et al., 2005) . Similarly, the matrix proteoglycan lumican (LUM), which is also expressed in mesenchymal-like structures in pleomorphic adenomas of the salivary gland (Kusafuka et al., 2004) , plays a role in EMT of lens epithelial cells in response to injury (Saika et al., 2003) . Myoepithelial carcinoma or carcinoma with myoepithelial differentiation exhibits a partial or total spindle growth pattern (Rosai, 2004) . MCB is suggested to have a myoepithelial origin and express myoepithelial markers (Reis-Filho et al., 2003) . Interestingly, three of the MCB subclass-2-overexpressed genes, SPARC, TIMP3 and LUM, are differentially overexpressed in myoepithelium (Jones et al., 2004; Kusafuka et al., 2004) , and this might, in part, account for the sarcomatous (spindle) growth pattern seen in MCB. It is noteworthy that several of these potentially EMT-related genes have functions related to development, especially bone, cartilage and musculoskeletal development. How these genes participate in the process of EMT remains to be clarified in light of the pivotal role of EMT during embryonic development. Finally, the identification of both PDGFA and PDGFRA is of particular interest too. PDGF is a major growth factor for mesenchymal cells. A potential autocrine/paracrine loop of PDGFA and PDGFRA is implicated in epithelial-mesenchymal interaction during development (Xu et al., 2005) and is involved in the metastatic potential of TGF-b-induced EMT in breast cancer cells (Jechlinger et al., 2006) . Taken together, these data substantiate the role of an autocrine loop of PDGFA and PDGFRA in EMT, which underlies the pathogenesis of MCB and might also imply a novel application of STI571, an inhibitor of PDGFRA, to therapeutically interfere with metastasis in this cancer.
Using Snail-6SA-MCF7 cells as an in vitro model of EMT, we found the majority of the tested discriminator genes between MCBs and DCBs and in MCB subclass 2 were also up-regulated in Snail-6SA-MCF7 cells as compared to Snail-WT-MCF7 or MCF7 parental cells, thereby suggesting a potential role of these MCB-related genes in EMT. Furthermore, the in vivo immunolocalization of SPARC and PDGFRA in the sarcomatous component of MCB and demonstrating that genes such as VIM, SPARC, BMP2 and PDGFRA were upregulated in Snail-6SA-MCF7 cells indicates that some of those mesenchymal-or ECM-related genes, assumed to be restricted to mesenchymal or ECM, may also upregulate in carcinoma cells showing EMT. Collectively, these results validate our in vivo observation by showing that, in line with the features of EMT seen in MCBs, at least some of those genes differentially expressed in MCB are potentially related to EMT, and this in turn justifies the use of the mutantSnail transfectant as a valid model system for the study of EMT.
Finally, the distinctive gene expression profile of MCB and the diagnostic utility of these two sets of discriminator genes, respectively, for MCB and DCB and for MCB subclasses, were validated by analysing the gene expression profile of a previously diagnosed additional case of MCB-MS that was morphologically similar to MCB subclass 2 cancer. In line with the purely morphological classification, MCB-MS was not only clearly clustered together with the MCBs and separated from the DCBs on unsupervised clustering, but also precisely clustered with the MCBs and MCB subclass 2 on supervised hierarchical clustering using these two sets of discriminator genes. These results demonstrate the robustness of these discriminator gene sets in the hierarchical clustering analysis by showing the consistence between the purely morphological classification and the gene expression profiling of the microarray experiments.
Although SNAI1 (Snail) and SNAI2 (Slug), which encode zinc-finger proteins crucial in the development of EMT, were identified as MCB-overexpressed genes on SAM analysis at an FDR of 0.05 (data not shown), some genes that are known to be activated during EMT (Zavadil and Bottinger, 2005) were absent in this genome-wide screen. It is possible that some of the molecular participants in EMT could appear only transiently in certain stages during the process of EMT, especially in the context of primary tumors when EMT takes a long time (Thiery, 2002; Zavadil and Bottinger, 2005) . Alternatively, there might be potential differences in these molecular participants not only between embryonic development and cancer progression of different types, but also between in vitro and in vivo observations.
In conclusion, our study demonstrated distinctive gene profiling between MCBs and DCBs and validated the diagnostic utility of the discriminator gene sets. We elucidated and validated that certain genes differentially upregulated in MCB and MCB subclass 2 may have potential roles in EMT. The information derived from such global transcription profiling offers clues to the pathogenesis of MCB, and sheds light on the mechanisms underlying EMT, and through such approaches, novel potential prognostic factors of cancer are found.
Materials and methods
Tumor tissue samples and cell lines Surgical specimens of breast cancer tumor tissue were freshly collected and snap frozen from patients who underwent surgery at National Taiwan University Hospital (NTUH) between 1998 and 2005. Cancer samples containing relatively pure tumor, as defined by greater than 50% tumor cells per high-power field examined in a section adjacent to the tissue used, were included in this study. A total of four MCBs and 34 stage-matched DCBs were included. The microscopic slides from the patients' tumor specimens were reviewed by one of the authors (HCL) and the diagnosis and histological subclassification of cancers were confirmed in all cases. Normal breast tissues from six patients who underwent surgery for benign breast lesions were included for comparison. Linked clinicopathological data were obtained for all patients who contributed tumor specimens (Supplementary Table 5 ). One additional case of MCB (MCB-MS), provided by Min-Seng Su, MD, Ming-Seng Hospital, Taoyang, was used in the validation of microarray data. Studies using human tissues were approved by and conducted in accordance with the policies of the Institutional Review Board at NTUH. The wild-type MCF7 and Snail transfectants (Snail-WT-MCF7 and Snail-6SA-MCF7) were maintained in DMEM/F12 supplemented with 10% fetal calf serum.
Oligonucleotide microarray
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA), and followed by the RNeasy Mini Kit (Qiagen, Hilden, Germany). Extracted total RNA was amplified by a low RNA input fluor linear amp kit (Agilent Technologies, Foster City, CA, USA) during the in vitro transcription process (CyDye, PerkinElmer, Waltham, MA, USA). For the expression profiling of MCBs and DCBs, a human reference RNA pooled from 10 cell lines (Stratagene, La Jolla, CA, USA) served as the reference in the microarray comparison. Tumor RNA was labeled by Cy5 and RNA from human reference RNA was labeled by Cy3. Cy-labeled cRNA (2 mg) was fragmented to an average size of about 50-100 nucleotides by incubation with fragmentation buffer at 601C for 30 min. Correspondingly, fragmentedlabeled cRNA was then pooled and hybridized to the Human 1A (version 2) oligonucleotide microarray (Agilent Technologies) at 601C for 17 h. After washing and drying in nitrogen, the microarrays were scanned with the Agilent microarray scanner at 535 nm for Cy3 and at 625 nm for Cy5. Scanned images were analysed using Feature Extraction software (Agilent Technologies). Only the features with signal noise ratios >2.6 in either the Cy3 or Cy5 channel were retrieved for further analysis.
Hierarchical clustering
A hierarchical clustering algorithm, UPGMA (Unweighted Pair-Group Method with Arithmetic mean), was applied to group genes and samples on the basis of their similarities in expression. The clustering was performed on all 44 samples by selecting transcripts that varied by at least fourfold from the median of the sample set in at least one of the samples. This resulted in a filtered gene list of 4525 probes representing 4334 genes (22.4% of 20 173 probes) for the unsupervised analysis. Results were displayed using the Spotfire program (Spotfire Inc., Somerville, MA, USA).
Statistical analysis of microarrays
The potentially significant changes in expression between DCBs and MCBs and between MCB subclasses were analysed using the SAM method (http://www-stat.stanford.edu/Btibs/ SAM/). The filtered 4525 probes were performed with the SAM procedure, and a selection threshold was set at an FDR of 1 or 5%.
QRT-PCR
Total RNA from primary breast tumor tissues or cell lines was reverse transcribed into cDNA (Superscript II; Life Technologies Inc.). Primer sequences and the PCR program are described in Supplementary Table 6 . Quantitative values were obtained from the threshold cycle number (C t ) and the fold-change in expression was calculated using the DDC t method. Target genes measurements in all samples were both normalized to the internal control gene TATA box binding protein and human common reference RNA.
IHC and immunofluorescent staining
Paraffin sections from primary breast cancer tissues were stained by IHC as described previously (Lien et al., 2004) . Primary antibodies used in the IHC were as follows: monoclonal antibody against human SPARC (Biogenex, San Ramon, CA, USA), PDGFRA (Neomarker, Fremont, CA, USA), (DAKO, Glostrup, Denmark), E-cadherin and vimentin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For immunofluorescent staining, slides were incubated with primary mouse Ab (anti-vimentin, anti-E-cadherin or anti-CK), washed and incubated with FITC-conjugated secondary antibody (Ab), before counterstaining with DAPI. The slides were examined under a Zeiss Axioplan 2 fluorescence microscope fitted with an ApoTome slider.
Western blotting
Proteins from cell lysates were resolved on sodium dodecyl sulfate-polyacrylamide gels. Immunoblotting was performed with the addition of antibodies to E-cadherin, vimentin, cytokeratin, actin and FLAG-tagged Snail, according to the manufacturer's protocol.
Tissue array and survival analysis One hundred and forty-four archives of breast cancer paraffin tissue blocks from the Department of Pathology at NTUH, with up to 11 years of clinical follow-up data, were arrayed in triplicate in a high-density tissue array, using an automated arrayer (Beecher Instruments, Sun Prairie, WI, USA). The clinicopathologic features are shown in Supplementary Table 7 . Statistical analyses were carried out using SPSS 12.0 software for Windows. The cumulative overall survival was calculated using the Kaplan-Meier method, and the log-rank test was used to analyse differences in the survival times.
